Literature DB >> 12219086

A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

Vasan K Sambandamurthy1, Xiaojuan Wang, Bing Chen, Robert G Russell, Steven Derrick, Frank M Collins, Sheldon L Morris, William R Jacobs.   

Abstract

With the advent of HIV and the widespread emergence of drug-resistant strains of Mycobacterium tuberculosis, newer control strategies in the form of a better vaccine could decrease the global incidence of tuberculosis. A desirable trait in an effective live attenuated vaccine strain is an ability to persist within the host in a limited fashion in order to produce important protective antigens in vivo. Attenuated M. tuberculosis vaccine candidates have been constructed by deleting genes required for growth in mice. These candidate vaccines did not elicit adequate protective immunity in animal models, due to their inability to persist sufficiently long within the host tissues. Here we report that an auxotrophic mutant of M. tuberculosis defective in the de novo biosynthesis of pantothenic acid (vitamin B5) is highly attenuated in immunocompromised SCID mice and in immunocompetent BALB/c mice. SCID mice infected with the pantothenate auxotroph survived significantly longer (250 days) than mice infected with either bacille Calmette-Guerin (BCG) vaccine or virulent M. tuberculosis (77 and 35 days, respectively). Subcutaneous immunization with this auxotroph conferred protection in C57BL/6J mice against an aerosol challenge with virulent M. tuberculosis, which was comparable with that afforded by BCG vaccination. Our findings highlight the importance of de novo pantothenate biosynthesis in limiting the intracellular survival and pathogenesis of M. tuberculosis without reducing its immunogenicity in vaccinated mice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12219086     DOI: 10.1038/nm765

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  142 in total

1.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

2.  Anamnestic responses of mice following Mycobacterium tuberculosis infection.

Authors:  Arati B Kamath; Samuel M Behar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Adenylating enzymes in Mycobacterium tuberculosis as drug targets.

Authors:  Benjamin P Duckworth; Kathryn M Nelson; Courtney C Aldrich
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

4.  Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis.

Authors:  Joseph Hinchey; Sunhee Lee; Bo Y Jeon; Randall J Basaraba; Manjunatha M Venkataswamy; Bing Chen; John Chan; Miriam Braunstein; Ian M Orme; Steven C Derrick; Sheldon L Morris; William R Jacobs; Steven A Porcelli
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

5.  Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Authors:  Vasan K Sambandamurthy; Steven C Derrick; Kripa V Jalapathy; Bing Chen; Robert G Russell; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

6.  Reduced local growth and spread but preserved pathogenicity of a DeltapurC Mycobacterium tuberculosis auxotrophic mutant in gamma interferon receptor-deficient mice after aerosol infection.

Authors:  Najmeeyah Brown; Muazzam Jacobs; Shreemanta K Parida; Tania Botha; Aldina Santos; Lizette Fick; Brigitte Gicquel; Mary Jackson; Valerie Quesniaux; Bernhard Ryffel
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

7.  Characterization of the protective T-cell response generated in CD4-deficient mice by a live attenuated Mycobacterium tuberculosis vaccine.

Authors:  Steven C Derrick; Teresa H Evering; Vasan K Sambandamurthy; Kripa V Jalapathy; Tsungda Hsu; Bing Chen; Mei Chen; Robert G Russell; Ana Paula Junqueira-Kipnis; Ian M Orme; Steven A Porcelli; William R Jacobs; Sheldon L Morris
Journal:  Immunology       Date:  2006-10-31       Impact factor: 7.397

8.  Safety and immunogenicity of the Mycobacterium tuberculosis DeltalysA DeltapanCD vaccine in domestic cats infected with feline immunodeficiency virus.

Authors:  Dawn M Zimmerman; W Ray Waters; Konstantin P Lyashchenko; Brian J Nonnecke; Douglas L Armstrong; William R Jacobs; Michelle H Larsen; Erin Egan; Gregg A Dean
Journal:  Clin Vaccine Immunol       Date:  2009-01-14

9.  Pathway-selective sensitization of Mycobacterium tuberculosis for target-based whole-cell screening.

Authors:  Garth L Abrahams; Anuradha Kumar; Suzana Savvi; Alvin W Hung; Shijun Wen; Chris Abell; Clifton E Barry; David R Sherman; Helena I M Boshoff; Valerie Mizrahi
Journal:  Chem Biol       Date:  2012-07-27

10.  PanG, a new ketopantoate reductase involved in pantothenate synthesis.

Authors:  Cheryl N Miller; Eric D LoVullo; Todd M Kijek; James R Fuller; Jason C Brunton; Shaun P Steele; Sharon A Taft-Benz; Anthony R Richardson; Thomas H Kawula
Journal:  J Bacteriol       Date:  2012-12-14       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.